Cargando…

Phase 1 randomized study on the safety, tolerability, and pharmacodynamic cognitive and electrophysiological effects of a dopamine D(1) receptor positive allosteric modulator in patients with schizophrenia

ASP4345, a novel dopamine D(1) receptor positive allosteric modulator, is being evaluated for the treatment of cognitive impairment associated with schizophrenia (CIAS). This phase 1 multiple ascending-dose study (NCT02720263) assessed the safety, tolerability, and pharmacodynamics of ASP4345 in pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Desai, Amit, Benner, Lauren, Wu, Ruishan, Gertsik, Lev, Maruff, Paul, Light, Gregory A., Uz, Tolga, Marek, Gerard J., Zhu, Tong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8182805/ https://www.ncbi.nlm.nih.gov/pubmed/33203954 http://dx.doi.org/10.1038/s41386-020-00908-0

Ejemplares similares

Pharmacokinetics of ASP4345 from Single Ascending-Dose and Multiple Ascending-Dose Phase I Studies
por: Desai, Amit, et al.
Publicado: (2020)

A randomized phase 1 single-dose polysomnography study of ASP8062, a GABA(B) receptor positive allosteric modulator
por: Walzer, Mark, et al.
Publicado: (2021)

Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor
por: Zhuang, Youwen, et al.
Publicado: (2021)

Single‐ and multiple‐dose safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of ASP0367, or bocidelpar sulfate, a novel modulator of peroxisome proliferator‐activated receptor delta in healthy adults: Results from a phase 1 study
por: Ito, Mototsugu, et al.
Publicado: (2021)

The Molecular Mechanism of Positive Allosteric Modulation at the Dopamine D1 Receptor
por: Goldberg, Alexander, et al.
Publicado: (2023)

The molecular mechanism of positive allosteric modulation at the dopamine D1 receptor
por: Goldberg, Alexander, et al.
Publicado: (2023)

The Dopamine Allosteric Agent, PAOPA, Demonstrates Therapeutic Potential in the Phencyclidine NMDA Pre-clinical Rat Model of Schizophrenia
por: Daya, Ritesh P., et al.
Publicado: (2018)

Endogenous dopamine release in the human brain as a pharmacodynamic biomarker: evaluation of the new GPR139 agonist TAK-041 with [(11)C]PHNO PET
por: Rabiner, Eugenii A., et al.
Publicado: (2021)

Enantioenriched Positive Allosteric Modulators Display Distinct Pharmacology at the Dopamine D(1) Receptor
por: Fyfe, Tim J., et al.
Publicado: (2021)

Dopamine Transporter (DAT1) and Dopamine Receptor D4 (DRD4) Genotypes Differentially Impact on Electrophysiological Correlates of Error Processing
por: Biehl, Stefanie C., et al.
Publicado: (2011)

A phase 1b/2a multicenter study of the safety and preliminary pharmacodynamic effects of selective muscarinic M(1) receptor agonist HTL0018318 in patients with mild‐to‐moderate Alzheimer's disease
por: Nathan, Pradeep J., et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor‐Positive Allosteric Modulator (D1PAM), in Healthy Subjects
por: Wilbraham, Darren, et al.
Publicado: (2020)

Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease
por: Wilbraham, Darren, et al.
Publicado: (2021)

Widespread Changes in Positive Allosteric Modulation of the Muscarinic M(1) Receptor in Some Participants With Schizophrenia
por: Hopper, Shaun, et al.
Publicado: (2019)

Functional Characterization of the Dopaminergic Psychostimulant Sydnocarb as an Allosteric Modulator of the Human Dopamine Transporter
por: Aggarwal, Shaili, et al.
Publicado: (2021)

The Role of Lipids in Allosteric Modulation of Dopamine D(2) Receptor—In Silico Study
por: Żuk, Justyna, et al.
Publicado: (2022)

A Randomized Multiple Dose Pharmacokinetic Study of a Novel PDE10A Inhibitor TAK-063 in Subjects with Stable Schizophrenia and Japanese Subjects and Modeling of Exposure Relationships to Adverse Events
por: Goldsmith, Paul, et al.
Publicado: (2017)

Electrophysiological Evidence in Schizophrenia in Relation to Treatment Response
por: Sueyoshi, Kazuki, et al.
Publicado: (2018)

Electrophysiological characterization of schizophrenia-associated variants in NaV1.2 sodium channel
por: Suslova, M., et al.
Publicado: (2022)

CENTRAL DOPAMINE AND SEROTONIN TURNOVER IN SCHIZOPHRENIA
por: Pandey, R.S., et al.
Publicado: (1987)

Abnormal Striatal Dopamine Transmission in Schizophrenia
por: Brunelin, Jerome, et al.
Publicado: (2013)

A challenge to the dopamine orthodoxy in schizophrenia?
por: Norman, Trevor R, et al.
Publicado: (2023)

An Allosteric Potentiator of the Dopamine D1 Receptor Increases Locomotor Activity in Human D1 Knock-In Mice without Causing Stereotypy or Tachyphylaxis
por: Svensson, Kjell A., et al.
Publicado: (2017)

GluD1, linked to schizophrenia, controls the burst firing of dopamine neurons
por: Benamer, N, et al.
Publicado: (2018)

Allosteric communication between protomers of dopamine Class A GPCR dimers modulates activation
por: Han, Yang, et al.
Publicado: (2009)

Allosteric modulatory effects of SRI-20041 and SRI-30827 on cocaine and HIV-1 Tat protein binding to human dopamine transporter
por: Sun, Wei-Lun, et al.
Publicado: (2017)

Electrophysiological and Neuropsychological Predictors of Conversion to Schizophrenia in At-Risk Subjects
por: Sumiyoshi, Tomiki, et al.
Publicado: (2013)

Preserved electrophysiological markers of confidence in schizophrenia spectrum disorder
por: Rouy, Martin, et al.
Publicado: (2023)

Maximum Tolerated Dose Evaluation of the AMPA Modulator Org 26576 in Healthy Volunteers and Depressed Patients: A Summary and Method Analysis of Bridging Research in Support of Phase II Dose Selection
por: Nations, Kari R., et al.
Publicado: (2012)

Allosteric mechanism for KCNE1 modulation of KCNQ1 potassium channel activation
por: Kuenze, Georg, et al.
Publicado: (2020)

New Genetic Findings in Schizophrenia: Is there Still Room for the Dopamine Hypothesis of Schizophrenia?
por: Nieratschker, Vanessa, et al.
Publicado: (2010)

2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D(1) Receptor for Parkinson’s Disease
por: García-Cárceles, Javier, et al.
Publicado: (2022)

Association of dopamine D1 receptor gene polymorphism with schizophrenia: a meta-analysis
por: Pan, Yuqing, et al.
Publicado: (2014)

Effects of the Dopamine D2 Allosteric Modulator, PAOPA, on the Expression of GRK2, Arrestin-3, ERK1/2, and on Receptor Internalization
por: Basu, Dipannita, et al.
Publicado: (2013)

Understanding the Allosteric Modulation of PTH1R by a Negative Allosteric Modulator
por: Li, Mengrong, et al.
Publicado: (2022)

Striatal dopamine, reward, and decision making in schizophrenia
por: Deserno, Lorenz, et al.
Publicado: (2016)

Schizophrenia, Dopamine and the Striatum: From Biology to Symptoms
por: McCutcheon, Robert A., et al.
Publicado: (2019)

Dysregulation of Midbrain Dopamine System and the Pathophysiology of Schizophrenia
por: Sonnenschein, Susan F., et al.
Publicado: (2020)

The role of dopamine receptors in lymphocytes and their changes in schizophrenia
por: Penedo, M.A., et al.
Publicado: (2021)

Low status, humiliation, dopamine and risk of schizophrenia
por: Selten, Jean Paul, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_17avvtcdfo7sb39b1uqg448fgu